Tuil E, Hommer A B, Poulsen P B, Christensen T L, Buchholz P, Walt J, Holmstrom S
CHNO des Quinze Vingts, Paris, France.
Int J Clin Pract. 2005 Sep;59(9):1011-6. doi: 10.1111/j.1742-1241.2005.00616.x.
Glaucoma is a condition affecting one or both eyes with raised intraocular pressure (IOP). IOP should be reduced to prevent progression of visual field loss. This study investigates the cost-effectiveness of bimatoprost compared with latanoprost as first-line monotherapies in the treatment of glaucoma in Austria, Finland and France. On the basis of a single multicentre, randomised, investigator-masked controlled trial, a 6- and 12-month cost-effectiveness model was designed following the treatment recommendations from the European Glaucoma Society. Treatment changes due to insufficient IOP reduction and adverse events were included. The cost-effectiveness analysis showed that the need for adjunctive therapy was the major cost driver. On the basis of evidence from the randomised, investigator-masked clinical trial (RCT), the cost-effectiveness analysis found that bimatoprost was a cheaper and a more effective treatment strategy compared with latanoprost. This was true for all three countries and all IOP targets between 13 and 20 mmHg. The cost-effectiveness result may be generalised to a European setting and perspective.
青光眼是一种影响一只或双眼且眼内压（IOP）升高的病症。应降低眼内压以防止视野丧失的进展。本研究调查了在奥地利、芬兰和法国，比马前列素与拉坦前列素作为青光眼一线单一疗法的成本效益。基于一项单一的多中心、随机、研究者设盲对照试验，根据欧洲青光眼协会的治疗建议设计了一个6个月和12个月的成本效益模型。纳入了因眼内压降低不足和不良事件导致的治疗变化。成本效益分析表明，辅助治疗的需求是主要的成本驱动因素。基于随机、研究者设盲临床试验（RCT）的证据，成本效益分析发现，与拉坦前列素相比，比马前列素是一种更便宜且更有效的治疗策略。对于所有三个国家以及13至20 mmHg之间的所有眼内压目标都是如此。成本效益结果可能适用于欧洲的情况和观点。
